1,375 results match your criteria Immunotherapy [Journal]


Regulatory B lymphocytes: development and modulation of the host immune response during disease.

Immunotherapy 2019 Apr 10. Epub 2019 Apr 10.

DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa, 8000.

The role of B lymphocytes (B cells) in immunogenic responses has become increasingly important over the past decade, focusing on a new B-cell subtype: regulatory B-cells (B). These B have been shown to possess potent immunosuppressive activities and have identified as key players in disease control and immune tolerance. In this review, the occurrence of B type in various conditions, along with evidence supporting discovered functions and proposed purposes will be explored. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0185
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0185DOI Listing
April 2019
4 Reads

Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.

Immunotherapy 2019 Apr 8. Epub 2019 Apr 8.

University of Western Ontario, Schulich School of Medicine & Dentistry, Department of Medicine, London, ON, Canada.

Several Janus kinase (JAK) inhibitors, oral targeted disease-modifying drugs, will be approved for the treatment of rheumatoid arthritis (RA) and other diseases. This review compares and contrasts the efficacy of JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib, peficitinib and decernotinib) in RA including: early RA methotrexate-naive patients, post methotrexate failure and post biologics. Trials in monotherapy, combination with disease modifying drugs such as methotrexate, and comparing with adalimumab in biologic-naive patients were studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0178DOI Listing

Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy.

Immunotherapy 2019 May;11(7):577-584

Department of Immunology, Mayo Clinic, Jacksonville, FL 32224, USA.

Immune checkpoint inhibitors have changed the treatment paradigm for patients with cancer. Though a majority of patients tolerate treatment, some develop hematologic toxicities, including eosinophilia. Eosinophilia has been associated with better responses in some patients with melanoma, but this has not been investigated in non-small-cell lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0128DOI Listing
May 2019
2 Reads

Corrigendum.

Authors:

Immunotherapy 2019 May;11(7):645

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0215c1DOI Listing

Efficacy of dendritic cell-based immunotherapy produced from cord blood in vitro and in a humanized NSG mouse cancer model.

Immunotherapy 2019 May;11(7):599-616

Department of Surgery, Hebei Medical University, 361 East Zhongshan Road,  Shijiazhuang 050017, China.

Aim: To produce dendritic cells (DCs) from CD34 stem cells from cord blood and explore their prophylactic and curative effect against tumors by vaccinating humanized NSG mice.

Materials & Methods: Separated CD34 stem cells from cord blood were cultured for 30 days, and the resultant DCs (CD34-DCs) were collected. The basic function of the CD34-DCs and the cytotoxicity of CD34-cytotoxic-T lymphocytes (CTLs) were tested in vitro, and tumor inhibition in a humanized NSG mouse tumor model was observed. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0103
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0103DOI Listing
May 2019
10 Reads

Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.

Immunotherapy 2019 May;11(7):591-598

Department of Haematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

The most recent progress in the oncology field has led to a paradigm shift in the management of cancer with the tsunami of immune checkpoint inhibitors that are associated with a particular pattern of immunological adverse events. This is a case of a 54-year-old woman that demonstrated a granulomatous reaction in the same dermatomal distribution of a previously treated shingles infection during treatment with an anti-programmed death 1 agent (pembrolizumab) for a newly diagnosed stage IV Hodgkin lymphoma. The purpose of this case is to increase the awareness of oncologists dealing with a new pattern of side effects taking into account the patient's background and recent exposures to latent viruses such as herpes zoster to prevent unnecessary diagnostic and therapeutic measures. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0169
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0169DOI Listing
May 2019
1 Read
2.440 Impact Factor

Immunotherapy for head and neck cancers: an update and future perspectives.

Immunotherapy 2019 May;11(7):561-564

Department of Otorhinolaryngology, Head & Neck Surgery, University of Ulm, Frauensteige 12, 89075 Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2019-0022DOI Listing

PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity.

Immunotherapy 2019 May;11(7):585-590

Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W120HS, UK.

Immune-related hepatitis is an important toxicity from immune-checkpoint inhibitor therapy, affecting up to 20% of patients on dual cytotoxic T-lymphocyte antigen 4/programmed cell death 1 (CTLA-4/PD-1) inhibitors. The mechanisms underlying this type of drug-induced liver injury are poorly understood. We report the case of a patient with immune-checkpoint inhibitor-related hepatitis where the presence of a diffuse granulomatous, PD-L1-positive infiltrate on liver biopsy correlated with poor response to corticosteroids. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0187
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0187DOI Listing
May 2019
2 Reads

Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.

Immunotherapy 2019 May;11(7):631-643

Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy.

Aim: Estimate prognosis and clinical outcome of patients with localized or metastatic renal cell carcinoma (RCC) is an important issue which drive our medical decisions.

Methods: We carried out a meta-analysis of available clinical studies exploring neutrophil-to-lymphocyte ratio (NLR) in RCC in order to evaluate if this ratio could be correlated to overall survival (OS) and progression-free survival (PFS) of patients with localized/metastatic RCC.

Results: In overall population higher NLR resulted in worst OS and PFS (OS pooled hazard ratio of 1. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0175
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0175DOI Listing
May 2019
2 Reads

New targeted therapies in spondyloarthritis: what are the limits?

Authors:
Daniel Wendling

Immunotherapy 2019 May;11(7):557-560

Professor of Rheumatology, Head of Department; Department of Rheumatology, University Hospital of Besançon & EA 4266 EPILAB, University of Franche-Comté, F-25030 Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2019-0007DOI Listing
May 2019
1 Read

Corrigendum.

Authors:

Immunotherapy 2019 Apr;11(6):555

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.14.81c1DOI Listing
April 2019
2 Reads

Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.

Immunotherapy 2019 Apr;11(6):515-529

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

The immune system is very important for monitoring and eradicating cancer cells. However, there may be multiple immunosuppressive mechanisms to prevent effective antitumor immunity in the tumor environment, such as the negative immunologic regulators known as checkpoints. Antibodies that block the checkpoints programmed cell death protein 1 (PD-1) pathway have made great success. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0173
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0173DOI Listing
April 2019
9 Reads

Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer.

Immunotherapy 2019 Apr;11(6):457-460

Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2019-0010DOI Listing
April 2019
5 Reads

Regulatory T and B cells in peripheral blood of subcutaneous immunotherapy-treated Japanese cedar pollinosis patients.

Immunotherapy 2019 Apr;11(6):473-482

Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka, Japan.

Aim: The aim of this study was to clarify whether there are more regulatory T (Treg) and regulatory B (Breg) cells, and higher levels of IL-10-related transcription factors in subcutaneous immunotherapy (SCIT)-treated pollinosis patients than in non-SCIT-treated patients.

Methods: Japanese cedar pollinosis patients undergoing SCIT had received treatment for at least 2.8 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0170DOI Listing

Recent clinical trials of immunotherapy in non-small-cell lung cancer.

Immunotherapy 2019 Apr;11(6):461-466

2nd Medical Oncology Department, Henry Dunant Hospital Center, Athens 11526, Greece.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2019-0021
Publisher Site
http://dx.doi.org/10.2217/imt-2019-0021DOI Listing
April 2019
4 Reads

Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model of human ovarian cancer.

Immunotherapy 2019 Apr;11(6):483-496

Cytokine Biology Section, Division of Intramural Research, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.

Aim:  We have shown that IL-4 fused to Pseudomonas exotoxin (IL-4-PE) is cytotoxic to ovarian cancer cell lines. The antineoplastic properties of IFN-α, IFN-γ and IL-4-PE have been studied and showed some promise in the clinical trials. Here, we investigated whether the combination of IL-4-PE, IFN-α and IFN-γ will result in increased ovarian cancer cell death in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439502PMC

Erratum.

Authors:

Immunotherapy 2019 Apr;11(6):556

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0081e1DOI Listing

Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing.

Immunotherapy 2019 May 12;11(7):565-575. Epub 2019 Mar 12.

Department of Gastroenterology, IBD Center, Humanitas Clinical & Research Center, 20089, Milan, Italy.

Anti-TNF-α have revolutionized the treatment of inflammatory bowel disease, but a significant proportion of patients do not respond or lose response over time after treatment with these drugs. Therefore, the development of drugs that act with a different mechanism of action is strongly needed. Vedolizumab is a selective blocker of intestinal integrin α4β7, which inhibits lymphocyte trafficking and blocks the inflammatory mechanism underlying the bowel damage of Crohn's disease and ulcerative colitis. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0209
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0209DOI Listing
May 2019
2 Reads

Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.

Immunotherapy 2019 May 11;11(7):617-629. Epub 2019 Mar 11.

Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.

Aim: Comparison of clinical outcomes of nivolumab + ipilimumab versus BRAF + MEK inhibitors (dabrafenib + trametinib or vemurafenib + cobimetinib) in BRAF-mutant advanced melanoma.

Methods: Matching-adjusted indirect comparisons were conducted between nivolumab + ipilimumab (CheckMate 067/069 studies) and BRAF + MEK inhibitors (COMBI-d, COMBI-v and coBRIM studies). Overall survival (OS), progression-free survival and objective response rates were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0208DOI Listing
May 2019
4 Reads

Corrigendum.

Authors:

Immunotherapy 2018 Oct;10(14):1285

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0183c1DOI Listing
October 2018
2 Reads

Corrigendum.

Authors:

Immunotherapy 2018 Oct;10(14):1287-1288

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0160c1DOI Listing
October 2018
1 Read

Recent advances in localized immunotherapy of skin cancers.

Immunotherapy 2019 Apr;11(5):443-456

Unit of Dermatology, University of Padua, Via Gallucci 4, Padova 35128, Italy.

Skin cancer is the most frequent malignancy in humans. The immune system has long been known to have an important role in defeating cancer. Immunotherapy, which includes various strategies to enhance tumor immunity, currently represents an exciting option for the treatment of skin cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0139DOI Listing

Nivolumab-associated digital small-vessel vasculitis in a patient with an advanced renal cell carcinoma.

Immunotherapy 2019 Apr;11(5):379-384

Department of Medical oncology, Puerta de Hierro University Hospital, Majadahonda, Spain.

The immunotherapy (IO) agents in the renal cell carcinoma represent the best option in the second line of treatment. However, these drugs can be associated with different types of toxicities. The vascular toxicity related with IO is very uncommon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0082DOI Listing
April 2019
2 Reads

Silencing PD-1 and PD-L1: the potential of PolyPurine Reverse Hoogsteen hairpins for the elimination of tumor cells.

Immunotherapy 2019 Apr;11(5):369-372

Department of Biochemistry & Physiology School of Pharmacy & Food Sciences & Institute of Nanoscience & Nanotechnology IN2UB University of Barcelona 08028 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0215DOI Listing
April 2019
2 Reads

Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue.

Immunotherapy 2019 Apr;11(5):365-368

Department of Medical, Surgery & Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0204DOI Listing
April 2019
1 Read

Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review.

Immunotherapy 2019 Apr;11(5):373-378

Department of Hematology, Taussig Cancer Center, Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USA.

Blinatumomab and donor lymphocyte infusion (DLI) combination is a promising cancer therapy, whereby blinatumomab might achieve an initial reduction in leukemic-cell burden using T cells, and after tumor clearance, DLI can potentially stimulate the donor immune system to achieve longer lasting remission. Here, we present a 51-year-old female with mixed phenotype acute leukemia who had a hematologic relapse 3 months after she received total body irradiation-based myeloablative allogeneic hematopoietic stem cell transplantation from an unrelated human leukocyte antigen matched (10/10) donor and achieved complete remission with minimal residual disease negativity by multi-parameter flow cytometry using the combination of blinatumomab and DLI. To the best of our knowledge, this is the first report to describe the use of blinatumomab and DLI combination therapy in the treatment of B/myeloid mixed phenotype acute leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439498PMC
April 2019
2 Reads
2.440 Impact Factor

Delayed IL-21 treatment preferentially expands peptide-specific CD8 T cells by reducing bystander activation of T cells.

Immunotherapy 2019 Apr 14;11(6):497-513. Epub 2019 Feb 14.

Biomedicine Production Branch, National Cancer Center, Goyang, 10408 Korea.

Aim: We previously reported a simple and practical procedure to generate peptide-specific CD8 T cells using peptide and IL-2, which is applied to produce human telomerase reverse transcriptase (hTERT)-specific CD8+ T cells for clinical use. We have modified the procedure to enhance the amplification of peptide-specific CD8 T cells adding IL-21.

Materials & Methods: Using human leukocyte antigen (HLA)-A*0201-restricted cytomegalovirus/pp65-specific CD8 T cells of healthy volunteers, we optimized the culture conditions by adjusting the dose and timing of IL-21 treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0095DOI Listing
April 2019
1 Read

Heat-shock proteins in diagnosis and treatment: an overview of different biochemical and immunological functions.

Immunotherapy 2019 Feb;11(3):215-239

Department of Hepatitis & AIDS, Pasteur Institute of Iran, Tehran, Iran.

Heat-shock proteins (HSPs) have been involved in different functions including chaperone activity, protein folding, apoptosis, autophagy and immunity. The HSP families have powerful effects on the stimulation of innate immune responses through Toll-like receptors and scavenger receptors. Moreover, HSP-mediated phagocytosis directly enhances the processing and presentation of internalized antigens via the endocytic pathway in adaptive immune system. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0105
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0105DOI Listing
February 2019
11 Reads

Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?

Immunotherapy 2019 Feb;11(3):161-166

Medical Oncology Unit, Department of General and Specialistic Medicine, University Hospital of Parma, 43126 Parma, Italy.

A patient diagnosed with centrally located advanced lung adenocarcinoma with signs of large vessels infiltration, strongly expressing PD-L1, was candidate to first-line pembrolizumab. He had not complained of any bleeding manifestation before immunotherapy. 5 days after the first dose of pembrolizumab, the patient experienced massive, fatal hemoptysis. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0136
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0136DOI Listing
February 2019
6 Reads
2.440 Impact Factor

Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.

Immunotherapy 2019 Feb;11(3):167-175

Department of Oncologic Imaging, National Cancer Centre, Singapore, 169610, Singapore.

Immune checkpoint inhibitors (ICIs) have demonstrated promising results in a variety of advanced cancer types. The phenomenon of hyperprogressive disease (HPD) has only been documented in recent years, however, there have been no reports of HPD in hepatocellular carcinoma. We present a case series of six patients with advanced hepatocellular carcinoma treated with ICIs who demonstrated rapid radiological progression, this was confirmed by comparing tumor growth rates before and during treatment with HPD defined as tumor growth rate ≥2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0126DOI Listing
February 2019
5 Reads

Enhancing tumor T cell infiltration to enable cancer immunotherapy.

Immunotherapy 2019 Feb;11(3):201-213

Center of Integrated Protein Science Munich (CIPS-M) & Division of Clinical Pharmacology, Klinikum der Universität München, Lindwurmstrasse 2a, 80337 Munich, Germany, Member of the German Center of Lung Research.

Cancer immunotherapy has changed the treatment landscape for cancer patients, especially for those with metastatic spread. While the immunotherapeutic armamentarium is constantly growing, as exemplified by approved compounds, clinical outcome remains variable both within and across entities. A sufficient infiltration into the tumor microenvironment and successful activation of effector T lymphocytes against tumor cells have been identified as predictors for responses to T cell-based immunotherapies. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0111
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0111DOI Listing
February 2019
3 Reads

Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis.

Immunotherapy 2019 Feb;11(3):189-199

Department of Medicine, Division of Oncology, University of Texas Health Sciences Center, Houston, TX, USA.

Aim: In this meta-analysis, we evaluated several predictors of benefit to single-agent immune checkpoint inhibitors (ICIs) in metastatic non-small-cell lung cancer (NSCLC).

Patients & Methods: Using the random-effect model, we assessed the comparative efficacy of ICIs over chemotherapy according to age, gender, smoking history, PD-L1 status and CNS involvement.

Results: Eight randomized trials were selected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0086DOI Listing
February 2019
5 Reads

Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases.

Immunotherapy 2019 Feb;11(3):241-254

Department of Oncology & Onco-Hematology, University of Milan, 20162, Milan, Italy.

The aim of this review is to report the current evidence on immunogenicity of monoclonal antibodies (moAbs) used in cancer compared with autoimmune diseases, focusing on local microenvironment. English abstracts were identified in Medline and www.clinicaltrials. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0081
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0081DOI Listing
February 2019
13 Reads

Fast up-dosing with a birch allergoid is safe and well tolerated in allergic rhinitis patients with or without asthma.

Immunotherapy 2019 Feb;11(3):177-187

Department for Children & Adolescents, Division for Allergology, Pneumology & Cystic Fibrosis, University Hospital Goethe University, Frankfurt am Main, 60590, Germany.

Aim: Subcutaneous immunotherapy is effective in treating allergic rhinoconjunctivitis and asthma, but is still inconvenient when heavy schedules are used. A faster dose escalation is desirable.

Materials & Methods: In this open-label, Phase II trial, 130 adults were randomized 1:1 to receive a birch pollen allergoid subcutaneous immunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0143DOI Listing
February 2019
2 Reads

Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update.

Immunotherapy 2019 Feb;11(3):149-153

Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0167DOI Listing
February 2019
1 Read
2.440 Impact Factor

The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.

Immunotherapy 2019 Feb;11(3):155-159

Department of Medicine, Section of Hematology/Oncology, The University of Chicago, 5841 South Maryland Ave, MC 2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0171DOI Listing
February 2019

Future perspectives of therapeutic monoclonal antibodies.

Immunotherapy 2019 Feb;11(2):119-127

Molecular Bioengineering Laboratory, Division of Chemistry for Materials, 1577 Kurima-Machiya-cho, Tsu, Mie 514-8507, Japan.

Attention to therapeutic monoclonal antibodies has been dramatically increasing year by year. Their highly specific targeting of antigens can provide very effective medical treatment, and the advent of molecular-targeting medicine is allowing development of a new generation of therapeutic agents. However, there is one critical obstacle to overcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0130DOI Listing
February 2019
1 Read

The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

Immunotherapy 2019 Feb;11(2):129-147

Department of Biology, University of Texas at San Antonio, TX 78249, USA.

While the etiology of multiple sclerosis (MS) remains unclear, research from the clinic and preclinical models identified the essential role of inflammation and demyelination in the pathogenesis of MS. Current treatments focused on anti-inflammatory processes are effective against acute episodes and relapsing-remitting MS, but patients still move on to develop secondary progressive MS. MS progression is associated with activation of microglia and astrocytes, and importantly, metabolic dysfunction leading to neuronal death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354220PMC
February 2019

Visualizing microbiome-immune system interplay.

Immunotherapy 2019 Feb;11(2):63-67

School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354219PMC
February 2019

The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy.

Immunotherapy 2019 Feb;11(2):75-79

Department of Immunology, Mayo Clinic Florida, 4500 San Pablo Road S, Jacksonville, FL 32224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0129DOI Listing
February 2019
3 Reads

Immunotherapy: a 10-year anniversary issue.

Authors:
Mike Gregg

Immunotherapy 2019 Feb;11(2):61-62

Future Science Group, Unitec House, 2 Albert Place, London N3 1QB, UK.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0189
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0189DOI Listing
February 2019
10 Reads

Prostate cancer: any room left for immunotherapies?

Immunotherapy 2019 Feb;11(2):69-74

Cancer Immunology & Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0159
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0159DOI Listing
February 2019
9 Reads

Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report.

Immunotherapy 2019 Apr 7;11(6):467-472. Epub 2019 Feb 7.

Department of Thoracic Oncology & Respiratory Medicine, Tokyo Metropolitan Cancer & Infectious Diseases Center, Komagome Hospital, Bunkyo, Tokyo, Japan.

Immuno-checkpoint inhibitor response and immune-related adverse events remain controversial issues. Managing pericardial effusion during programmed cell death 1 inhibitor treatment is challenging. Here, we report a case of successfully managed cardiac tamponade caused by nivolumab-induced pseudoprogression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2019-0003DOI Listing
April 2019
4 Reads

Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.

Immunotherapy 2019 Apr 4;11(5):407-428. Epub 2019 Feb 4.

Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77005, USA.

Aim: A systematic review and network meta-analysis were conducted to evaluate the efficacy of pembrolizumab + pemetrexed + platinum relative to other regimens in metastatic nonsquamous non-small-cell lung cancer (NSq-NSCLC).

Patients & Methods: Eligible studies evaluated first-line regimens in NSq-NSCLC patients without known targetable mutations. Relative treatment effects were synthesized with random effects proportional hazards Bayesian network meta-analyses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0193DOI Listing

Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma.

Immunotherapy 2019 Jan;11(1):21-35

Department of Medical Oncology, University Hospital of Parma, Parma, 43126, Italy.

Aim: The knowledge of the immune context of renal cell carcinoma (RCC) is useful to predict benefit from immunotherapy. We retrospectively characterized the immune context of RCC patients underwent primary nephrectomy and pulmonary metastasectomy.

Materials & Methods: Intratumoral infiltrating lymphocytes and peritumoral renal infiltrating lymphocytes, lymphocyte subpopulations (CD4, CD8), PD-1, PD-L1 were explored in paired samples of primary RCC (T) and respective pulmonary metastases (M). Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0097
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0097DOI Listing
January 2019
9 Reads
2.440 Impact Factor

The complicated effects of  obesity on cancer and immunotherapy.

Immunotherapy 2019 Jan;11(1):11-14

Department of Dermatology, UC Davis School of Medicine, Sacramento, CA 95816, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0133DOI Listing
January 2019

Biologics for hidradenitis suppurativa: an update.

Immunotherapy 2019 Jan;11(1):45-59

Department of Dermatology, Venereology & Allergology, Medical University, Wroclaw, Poland.

Hidradenitis suppurativa (HS) is a chronic, inflammatory dermatosis characterized by an occurrence of nodules, abscesses, sinus tracks and scarring. Its pathogenesis is multifactorial and still not fully understood, therefore, current systemic therapies still remain a serious challenge. Increased levels of several proinflammatory cytokines have been reported in patients suffering from HS, therefore biologics appear as a new approach to therapy for this condition. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0090
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0090DOI Listing
January 2019
7 Reads

Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.

Immunotherapy 2019 Jan;11(1):37-44

Department of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, People's Republic of China.

The chimeric antigen receptor T (CAR-T) cells play an antileukemia role, and can be used to treat or prevent relapse by targeting minimal residual disease for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the infusion of allogeneic CAR-T cells may also cause graft-versus-host disease, which limited their applications during and after allo-HSCT. In this review, we discuss the clinical trials that applying CAR-T cells before allo-HSCT and the use of donor-derived CAR-T cells as conditioning regimen during allo-HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0089DOI Listing
January 2019
1 Read
2.440 Impact Factor

Update on the current revolution in cancer immunotherapy.

Immunotherapy 2019 Jan;11(1):15-20

Department of Biochemistry, Cancer Biology, Neuroscience & Pharmacology, School of Medicine, Meharry Medical College, Nashville, TN, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0135
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0135DOI Listing
January 2019
4 Reads

Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?

Immunotherapy 2019 Jan;11(1):3-6

Department of Researchand Development, Chiesi Farmaceutici, Parma, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0119DOI Listing
January 2019
2 Reads
2.440 Impact Factor